When should I start treatment for Neuroendocrine Tumors vs watchful waiting

Treatment vs. Watchful Waiting for Neuroendocrine Tumors

This is one of the most important decisions you'll face with a neuroendocrine tumor (NET), and the answer depends heavily on your specific situation. Let me walk you through how doctors think about this decision.

How Oncologists Approach This Decision

According to the NCCN Guidelines for Neuroendocrine Tumors, the decision between starting treatment and watchful waiting (also called "observation") depends on several key factors:

1. Tumor Grade & Differentiation

• Well-differentiated, low-grade tumors (Grade 1-2) often grow slowly and may be candidates for observation
• Poorly-differentiated or high-grade tumors typically require prompt treatment
• Your pathology report's Ki-67 index (a measure of how fast cells are dividing) is critical here

2. Tumor Burden & Symptoms The NCCN Guidelines distinguish between:

• Asymptomatic, low tumor burden, stable disease → Observation with regular monitoring is often appropriate
• Symptomatic disease → Treatment is typically recommended
• Clinically significant progressive disease → Treatment is needed

3. Functional vs. Non-Functional Tumors

• Functional tumors (producing hormones causing symptoms like carcinoid syndrome, hypoglycemia, or diarrhea) → Usually treated to control symptoms
• Non-functional tumors → May be observed if stable and asymptomatic

4. Metastatic Disease If your cancer has spread to distant sites (like the liver or bones), treatment is generally recommended rather than observation alone.

General Treatment Approaches That Exist

For patients found to have well-differentiated NETs with low tumor burden and stable disease, doctors typically consider:

• Somatostatin analogs (octreotide LAR or lanreotide) - medications that slow tumor growth and control hormone-related symptoms
• Observation with imaging surveillance - regular CT/MRI scans and blood work to monitor for changes
• Combination approaches - observation initially, then adding treatment if disease progresses

For more aggressive or progressive disease, options expand to include:

• Systemic chemotherapy
• Targeted therapies
• Liver-directed therapies (for liver-predominant disease)
• Radiation therapy

Questions to Ask Your Oncology Team

Since YOUR specific situation requires your doctor's evaluation, here are critical questions to guide your discussion:

1. What is my tumor grade, Ki-67 index, and stage? (These directly determine treatment urgency)

2. Is my tumor functional or non-functional, and am I experiencing any hormone-related symptoms? (Functional tumors causing symptoms usually need treatment)

3. What is my current tumor burden, and is there evidence of disease progression? (Stable, low-burden disease may warrant observation; progressive disease needs treatment)

4. If we choose observation, what monitoring schedule do you recommend? (How often will we do imaging and blood work?)

5. What are the specific triggers that would prompt us to start treatment if we begin with observation? (This helps you understand what changes matter)

6. What treatment options would be most appropriate for my specific tumor type and genetics? (Different NET locations and mutations respond to different therapies)

Important Context: The Surveillance Approach

According to NCCN Guidelines, if observation is chosen, your care team will typically recommend:

• Regular imaging (multiphasic CT or MRI) every 3-12 months
• Biochemical marker testing (like chromogranin A levels)
• Clinical assessment for new symptoms

This allows doctors to catch progression early while avoiding unnecessary treatment side effects in patients with indolent (slow-growing) disease.

Key Takeaway

The decision between treatment and watchful waiting is not one-size-fits-all. A patient with a small, stable, well-differentiated pancreatic NET might reasonably observe for years. A patient with a poorly-differentiated tumor or evidence of rapid growth would typically start treatment promptly.

Your oncologist will determine the most appropriate approach for YOUR case based on your complete clinical picture, including pathology findings, imaging results, symptoms, and your overall health status.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Neuroendocrine Tumors (Version 3.2025); NCCN Guidelines for Patients: Neuroendocrine Tumors